Print Page  Close Window

Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

NASDAQ | AVEO (Common Stock)
$0.59 - 0.01
Stock chart for: AVEO.O.  Currently trading at $0.59 with a 52 week high of $1.15 and a 52 week low of $0.50.
04/25/17 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Announces Presentations at the 2017 ASCO Annual MeetingRead More
AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding IssuesRead More
AVEO Announces Milestone Payment from CANbridge for AV-203Read More